艺妙神州成立于2015年，注册资本3000万元，是一家致力于恶性肿瘤治疗的基因细胞药物的企业，中关 村科学城、水木基金、阳光诺和等参与投资。 公司控股股东为董事长兼总经理何霆，毕业于清华大学癌症生物学实验室，何霆直接及间接合计控制公 司21.92%股权。 官网显示，公司承担了十多项国家级和省级科研课题，与北京肿瘤医院、清华长庚医院、北京协和医 院、北医三院、北京大学人民医院等顶尖医院共同开展CAR-T药物临床研究，获批国家高新技术企业、 博士后科研工作站、北京市工程研究中心、北京市专精特新企业、CAR-T联合研发中心等平台或资质。 | 辅导对象 | 北京艺妙神州生物医药股份有限公司(以下简称"艺妙神州""公 司") | | --- | --- | | 成立日期 | 2015年4月14日 | | 注册资本 | 法定代表人 何宴 3,000 万元人民币 | | 注册地址 | 北京市海淀区杏石口路80号B区1号楼3层316号 | | 控股股东及 持 股 比 例 | 何霆,直接及间接合计控制公司 21. 92%股权 | | 行业分类 | 在其他交易场 医药制造业(C27) 所(申请)挂牌 无 或上市的情况 | | 备 ...

Core Viewpoint - Beijing Yimiao Shenzhou Biopharmaceutical Co., Ltd. is advancing its IPO process on the Sci-Tech Innovation Board, having signed a counseling agreement with CITIC Securities on July 23 this year [2]. Company Overview - Founded in 2015, Yimiao Shenzhou focuses on innovative drug development using original research gene cell therapy for major diseases such as cancer and autoimmune diseases [2]. - The company has developed a one-stop platform for gene cell drug research and industrialization, with 7 clinical trial approvals in China and 1 in the United States for CAR-T new drugs [2]. Product Pipeline - The research pipeline includes treatments for hematological tumors such as lymphoma, leukemia, and myeloma, as well as solid tumors like liver cancer, gastric cancer, colorectal cancer, and melanoma [2]. - The CAR-T product IM19 targets relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) and has submitted a New Drug Application (NDA) in China, which has been accepted [3]. - IM96 is the only CAR-T candidate drug globally that has received clinical trial approval in both China and the United States, specifically targeting GUCY2C [4]. Market Position - IM19's innovative CAR molecular design and production process provide more specific therapeutic effects, significantly improving survival time and quality of life for r/r DLBCL patients, thus filling a market gap for domestically developed CAR-T therapies in China [3]. - IM96 has been approved for treating colorectal cancer in China, marking it as the first CAR-T candidate for this indication in the country [4]. Financing and Investment - Yimiao Shenzhou has completed a total of 10 financing rounds since its establishment, with investors including Foothill Ventures, Tsinghua x-lab, and several other venture capital firms and funds [4].